Rhythm Biosciences (ASX:RHY) shares climbed again today after achieving its latest milestone – completing a prototype test kit. The company is … Read More
The post Rhythm Biosciences proves its colorectal cancer test is for real; shares up nearly 600pc in 8 months appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.